Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. März 2020 09:00 ET | Quelle: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Files Registration Statement for a Proposed Initial Public Offering

STANS, Switzerland, March 02, 2020 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
30. September 2019 10:00 ET | Quelle: NLS Pharmaceutics

NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio

STANS, Switzerland, Sept. 30, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
03. September 2019 08:00 ET | Quelle: NLS Pharmaceutics

NLS Announces Appointment of Industry Veteran Dr. Sandy Eisen as Chief Medical Officer

STANS, Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases, including...
13. August 2019 13:04 ET | Quelle: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity

STANS, Switzerland, Aug. 13, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including...
03. Juli 2019 09:00 ET | Quelle: NLS Pharmaceutics

NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio

STANS, Switzerland, July 03, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments for the Central Nervous System (CNS) in...
19. März 2019 16:05 ET | Quelle: NLS Pharmaceutics

NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®

STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder...
21. Februar 2019 08:00 ET | Quelle: NLS-1 Pharma AG

NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America

STANS, Switzerland, Feb. 21, 2019 (GLOBE NEWSWIRE) -- NLS-1 Pharma (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and...